Third Tysabri adverse case hits drug class

Theoretical concerns about drug ring true but many questions remain unanswered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Authors

Cormac Sheridan
View author publications
You can also search for this author in PubMed Google Scholar

Sheridan, C. Third Tysabri adverse case hits drug class. Nat Rev Drug Discov 4, 357–358 (2005). https://doi.org/10.1038/nrd1743

RNAi-based therapeutic strategies for metabolic disease
- Michael P. Czech
- Myriam Aouadi
- Gregory J. Tesz
Nature Reviews Endocrinology (2011)
Case histories, magic bullets and the state of drug discovery
- Jürgen Drews
Nature Reviews Drug Discovery (2006)
The problem with potency
- Christopher Thomas Scott
Nature Biotechnology (2005)
Natalizumab and PML
- Richard M Ransohoff
Nature Neuroscience (2005)